Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

The vaccine contains inactivated influenza B virus particles that act as antigens. When injected, they are taken up by antigen‑presenting cells, which trigger B‑cell activation and the production of strain‑specific antibodies. These antibodies neutralise the virus, preventing infection if the person is later exposed.

The dosing regimen for Influvac Tetra is determined by the prescribing healthcare professional based on age, health status, and local immunisation guidelines. Typically, a single dose is administered intramuscularly or subcutaneously, but the exact volume and schedule are set by the clinician.

Safety data for Influvac Tetra in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits and risks before vaccinating pregnant or breastfeeding individuals. Consultation with a medical professional is recommended to make an informed decision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Influvac Tetra is a quadrivalent formulation that specifically includes two influenza B strains, offering broader protection against B lineages compared with some trivalent vaccines that contain only one B strain. Its efficacy and safety profile are comparable to other licensed influenza vaccines, but the exact choice depends on regional strain circulation and clinical guidelines.

Influvac Tetra must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before use, allow the product to reach room temperature if required, and discard any vial that has been exposed to temperatures outside the recommended range.

The vaccine is given by a single intramuscular or subcutaneous injection, usually into the deltoid muscle of the upper arm. Administration should be performed by a qualified healthcare professional following aseptic technique and standard vaccination protocols.

The most serious adverse events reported include severe allergic reactions such as anaphylaxis and rare neurological conditions like Guillain‑Barré syndrome. Immediate medical attention is required if symptoms of a severe reaction appear after vaccination.

Individuals with a documented severe allergy to any component of the vaccine, or those who have experienced a previous severe reaction to an influenza B vaccine, should not receive Influvac Tetra. Contra‑indications should be confirmed by a healthcare professional before vaccination.